Status:
TERMINATED
Nitrous Oxide Analgesia Vaso-occlusive Crisis
Lead Sponsor:
Columbia University
Conditions:
Sickle Cell Disease
Vaso-occlusive Crisis
Eligibility:
All Genders
8-18 years
Phase:
PHASE2
Brief Summary
Patients who have sickle cell VOC are usually treated with opioids, such as morphine. However, this current way of treating them has not improved the health, medical outcomes, or rates of hospitalizat...
Eligibility Criteria
Inclusion
- Patients with sickle cell disease
- Ages 8 to 18, inclusive
- Present to the pediatric emergency department with VOC and whose pain scores remain greater than or equal to 7/10 on the NRS after initial standard treatment (i.e. IV fluids, morphine and NSAIDs).
Exclusion
- life-threatening illness as determined by attending clinician
- developmental delay
- altered level of consciousness
- any contraindications to receiving N2O
- foster children and wards of the state
Key Trial Info
Start Date :
November 12 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 19 2018
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT01891812
Start Date
November 12 2013
End Date
January 19 2018
Last Update
July 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York Presbyterian Morgan Stanley Children's Hospital
New York, New York, United States, 10032